Reexpression of the Major PKC Substrate, SSeCKS, Correlates with the Tumor‐Suppressive Effects of SCH51344 on Rat‐6/src and Rat‐6/ras Fibroblasts but Not on Rat‐6/raf Fibroblasts

IH Gelman,QR Xi,CC Kumar

DOI: https://doi.org/10.1111/j.1749-6632.1999.tb09421.x

1999-01-01

Abstract:Oncogenes such as v-src and v-ras induce oncogenic transformation by activating at least two signaling pathways, a Raf-Mek-Erk pathway controlling proliferationinducing transcription, and pathways involving Rho-family GTPases that regulate both proliferation and control of cytoskeletal architecture. SCH51344 is a pyrazoloquinoline derivative that was isolated by its ability to derepress a transformationsensitive α-actin isoform and was subsequently shown to suppress ras-induced oncogenic transformation by inhibiting membrane ruffling controlled by the Rho-family member, Rac.1–3 Because SCH51344 does not inhibit ras activation of either Erk or Jnk, this drug is thought to mediate tumor suppression by reestablishing controls on actin-based cytoskeletal organization rather than by affecting proliferative signaling. We previously described a new cell cycle-regulated protein kinase C (PKC) substrate, SSeCKS, that interacts with and modulates the organization of the actin-based cytoskeleton.4–7 SSeCKS expression is downregulated in srcand ras-, but not in raf-transformed rodent fibroblasts,4 and its reexpression in src-transformed fibroblasts or ras-transformed prostate cancer epithelial cells suppresses anchorageand mitogen-independence and reestablishes contact-inhibited growth and cytoskeletal organization.8 SSeCKS also shares significant similarity with human Gravin, a scaffolder of kinases such as PKC and PKA.9 Therefore, we surmised that SSeCKS expression might serve as a marker for oncogenes that alter the critical cytoskeletal control pathways involved in transformation. Here we ask if SCH51344 could derepress SSeCKS and if this correlates with a loss of anchorage independence in src-, ras-, and raf-transformed rat-6 fibroblasts.